Ensuring Center Quality, Proper Patient Selection and Fair Access to Chimeric Antigen Receptor T-Cell Therapy: Position Statement of the Austrian CAR-T Cell Network

Memo - Magazine of European Medical Oncology - Austria
doi 10.1007/s12254-020-00582-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Molecular Therapy - Oncolytics
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

International Journal of Hematology
Hematology
2020English

Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy

British Journal of Haematology
Hematology
2018English

An Introduction to Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Human Cancer

American Journal of Hematology
Hematology
2019English

Advancing Chimeric Antigen Receptor T Cell Therapy With CRISPR/Cas9

Protein & Cell
BiochemistryBiotechnologyDrug DiscoveryCell BiologyMedicine
2017English

Cytokine Release Syndrome With Chimeric Antigen Receptor T Cell Therapy

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Prospects to Improve Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Immunotherapy
OncologyAllergyImmunology
2016English

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

JAMA Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy